[vc_row][vc_column width=”1/6″][/vc_column][vc_column css_animation=”fadeInUp” width=”2/3″][vc_custom_heading text=”Sarepta Acquires Investigational Gene Therapy for LGMD2A” use_theme_fonts=”yes”][vc_empty_space height=”10px”][vc_column_text]Sarepta Therapeutics has executed an exclusive license agreement for a gene therapy candidate that aims to treat limb-girdle muscular dystrophy type 2A (LGMD2A), the company announced.
The investigational therapy, called calpain 3 or CAPN-3, was developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, in Columbus, Ohio.
The deal followed a number of successful preclinical and safety studies led by Zarife Sahenk, MD, PhD, an attending neurologist at the hospital.
Mas información[/vc_column_text][/vc_column][vc_column width=”1/6″][/vc_column][/vc_row]